Omicron proof vaccine patents must be waived
In a rare piece of good COVID-19 news, researchers in Texas are developing a COVID-19 vaccine called Corbevax that developers say will be based on conventional vaccine technology, will be cheaper to produce and less complicated to store. Crucially, they do not intend to patent the vaccine, hoping this will make it more accessible in low-income countries.